AR066473A1 - Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancer - Google Patents
Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancerInfo
- Publication number
- AR066473A1 AR066473A1 ARP080101932A ARP080101932A AR066473A1 AR 066473 A1 AR066473 A1 AR 066473A1 AR P080101932 A ARP080101932 A AR P080101932A AR P080101932 A ARP080101932 A AR P080101932A AR 066473 A1 AR066473 A1 AR 066473A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- ethyl
- methyl
- hydroxy
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 Triazolyl aminopyrimidine compound Chemical class 0.000 abstract 21
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 208000033781 Thyroid carcinoma Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93834707P | 2007-05-16 | 2007-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066473A1 true AR066473A1 (es) | 2009-08-19 |
Family
ID=39951591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101932A AR066473A1 (es) | 2007-05-16 | 2008-05-07 | Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8063035B2 (enExample) |
| EP (1) | EP2155734A2 (enExample) |
| JP (1) | JP5248600B2 (enExample) |
| KR (1) | KR101131261B1 (enExample) |
| CN (1) | CN101679395B (enExample) |
| AR (1) | AR066473A1 (enExample) |
| AU (1) | AU2008254319B2 (enExample) |
| BR (1) | BRPI0811433A2 (enExample) |
| CA (1) | CA2691997A1 (enExample) |
| CL (1) | CL2008001323A1 (enExample) |
| EA (1) | EA016781B1 (enExample) |
| MX (1) | MX2009012228A (enExample) |
| PE (1) | PE20090216A1 (enExample) |
| TW (1) | TW200908981A (enExample) |
| WO (1) | WO2008144223A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| AU2007334040B2 (en) | 2006-12-21 | 2012-02-16 | Eli Lilly And Company | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| JP5166441B2 (ja) | 2006-12-21 | 2013-03-21 | イーライ リリー アンド カンパニー | 癌治療用イミダゾリジノニルアミノピリミジン化合物 |
| US8440835B2 (en) | 2007-02-26 | 2013-05-14 | Massachusetts Institute Of Technology | Environmentally sensitive fluorophores |
| EA015574B1 (ru) | 2007-05-16 | 2011-10-31 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
| EA016781B1 (ru) | 2007-05-16 | 2012-07-30 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
| KR101123178B1 (ko) * | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| EP2470652A1 (en) * | 2009-08-25 | 2012-07-04 | OncoTherapy Science, Inc. | Ercc6l as target genes for cancer therapy and diagnosis |
| US8409820B2 (en) | 2009-08-31 | 2013-04-02 | Massachusetts Institute Of Technology | Kinase sensors |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| JP7090037B2 (ja) * | 2016-06-23 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体 |
| WO2020068600A1 (en) * | 2018-09-24 | 2020-04-02 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof |
| WO2021042169A1 (en) * | 2019-09-05 | 2021-03-11 | The University Of Melbourne | Nitrification inhibitors |
| CN112341428A (zh) * | 2020-11-04 | 2021-02-09 | 菏泽鸿特药业有限公司 | 一种噻吩-2-乙胺的生产方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929726A (en) * | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| WO2004063192A1 (en) | 2003-01-10 | 2004-07-29 | Pharmacopeia Drug Discovery, Inc. | Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| JP2007533602A (ja) * | 2003-07-31 | 2007-11-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾチオフェン化合物及びそれらの使用 |
| CN101115749B (zh) | 2004-12-17 | 2011-06-22 | 安姆根有限公司 | 氨基嘧啶化合物和使用方法 |
| TW200800201A (en) | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| JP5166441B2 (ja) * | 2006-12-21 | 2013-03-21 | イーライ リリー アンド カンパニー | 癌治療用イミダゾリジノニルアミノピリミジン化合物 |
| AU2007334040B2 (en) * | 2006-12-21 | 2012-02-16 | Eli Lilly And Company | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| EA015574B1 (ru) | 2007-05-16 | 2011-10-31 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
| EA016781B1 (ru) | 2007-05-16 | 2012-07-30 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
-
2008
- 2008-05-07 EA EA200971068A patent/EA016781B1/ru not_active IP Right Cessation
- 2008-05-07 WO PCT/US2008/062808 patent/WO2008144223A2/en not_active Ceased
- 2008-05-07 PE PE2008000798A patent/PE20090216A1/es not_active Application Discontinuation
- 2008-05-07 AU AU2008254319A patent/AU2008254319B2/en not_active Ceased
- 2008-05-07 CN CN2008800157689A patent/CN101679395B/zh not_active Expired - Fee Related
- 2008-05-07 BR BRPI0811433A patent/BRPI0811433A2/pt not_active IP Right Cessation
- 2008-05-07 EP EP08747731A patent/EP2155734A2/en not_active Withdrawn
- 2008-05-07 US US12/598,926 patent/US8063035B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2010508500A patent/JP5248600B2/ja not_active Expired - Fee Related
- 2008-05-07 MX MX2009012228A patent/MX2009012228A/es active IP Right Grant
- 2008-05-07 TW TW097116886A patent/TW200908981A/zh unknown
- 2008-05-07 CA CA002691997A patent/CA2691997A1/en not_active Abandoned
- 2008-05-07 KR KR1020097023340A patent/KR101131261B1/ko not_active Expired - Fee Related
- 2008-05-07 AR ARP080101932A patent/AR066473A1/es unknown
- 2008-05-07 CL CL2008001323A patent/CL2008001323A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101131261B1 (ko) | 2012-04-24 |
| US8063035B2 (en) | 2011-11-22 |
| PE20090216A1 (es) | 2009-02-28 |
| CN101679395A (zh) | 2010-03-24 |
| EP2155734A2 (en) | 2010-02-24 |
| CN101679395B (zh) | 2012-06-13 |
| MX2009012228A (es) | 2009-12-01 |
| US20100087431A1 (en) | 2010-04-08 |
| AU2008254319A1 (en) | 2008-11-27 |
| BRPI0811433A2 (pt) | 2016-03-22 |
| KR20090130242A (ko) | 2009-12-21 |
| WO2008144223A3 (en) | 2009-02-05 |
| AU2008254319B2 (en) | 2012-04-19 |
| JP2010527365A (ja) | 2010-08-12 |
| CL2008001323A1 (es) | 2009-05-29 |
| CA2691997A1 (en) | 2008-11-27 |
| WO2008144223A2 (en) | 2008-11-27 |
| EA200971068A1 (ru) | 2010-04-30 |
| EA016781B1 (ru) | 2012-07-30 |
| JP5248600B2 (ja) | 2013-07-31 |
| TW200908981A (en) | 2009-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066473A1 (es) | Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancer | |
| CY1122883T1 (el) | Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος | |
| PH12019501874A1 (en) | Crystal modifications | |
| AR071187A1 (es) | Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer | |
| CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
| MA33909B1 (fr) | Pyrrolidinones accoles en tant d'inhibiteurs de syk | |
| MX2010008035A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas. | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| MX384521B (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| ECSP099044A (es) | Compuestos de pirimido fusionados | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| BR112015008311A2 (pt) | conjugados fármaco-proteína | |
| CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| HN2009000455A (es) | Inhibidore de quinasa | |
| EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CL2010001468A1 (es) | Compuestos derivados de adamantildiamida, moduladores alostericos del receptor 5 glutamato metabotropico (mglur5); composicion farmaceutica que los comprende; y uso para tratar una enfermedad o trastorno del snc tal como depresion, ansiedad, esquizofrenia y enfermedad de parkinson. | |
| PE20141148A1 (es) | Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| AR083417A1 (es) | Composiciones farmaceuticas que contienen un dgat1 inhibidor | |
| AR087672A1 (es) | Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer | |
| EA201270428A1 (ru) | Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины | |
| PE20110677A1 (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |